Tag Archives: in vivo

Photoimmunotechnology as a powerful biological tool for molecular-based elimination of target cells and microbes, including bacteria, fungi and viruses

Published in: Nature Protocols Authors: Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga The Jikei University School of Medicine  Published in: Nature Protocols Authors: Tadayuki Iwase, Kimihiro Ito, Takashi Nishimura, Kei Miyakawa, Akihide Ryo, Hisataka Kobayashi, Makoto Mitsunaga The Jikei University School of Medicine Microbial pathogens, including bacteria, fungi and viruses, can develop resistance to clinically used drugs; therefore, finding new therapeutic agents is an ongoing challenge. Recently, we reported the photoimmuno-antimicrobial strategy (PIAS), a type of photoimmunotechnology, that enables molecularly targeted elimination of a wide range of microbes, including the viral pathogen severe acute respiratory syndrome coronavirus 2 and the multidrug-resistant bacterial pathogen Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2023

 Modulight Spotlights: LASER-SHARP RESEARCH – August 2023 Interleukin 15 (IL-15) is promising candidate for cancer immunotherapy, since it is an inducer of differentiation and proliferation of killer T cells and NK cells. A new study by Fukushima et al. at NCI, published in Molecular Cancer Therapeutics, shows increase in therapeutic efficacy in vivo when IL15 was combined with photoimmunotherapy using ML7710 laser system. Intratumoral injection of IL-15 also boosted the immune responses against both the primary tumor as well as abscopal effect eradicating distant, untreated tumor.​ ​​ Read original publication Modulight Continue reading →

Intratumoral interleukin-15 improves efficacy of near-infrared photoimmunotherapy

Published in: Molecular Cancer Therapeutics Authors: Hiroshi Fukushima, Aki Furusawa, Takuya Kato, Hiroaki Wakiyama, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: Molecular Cancer Therapeutics Authors: Hiroshi Fukushima, Aki Furusawa, Takuya Kato, Hiroaki Wakiyama, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   Interleukin 15 (IL-15) is inducer of differentiation and proliferation of CD8+ T cells and NK cells and thus promising candidate for cancer immunotherapy. This study showed therapeutic efficacy increase in vivo when IL15 was combined with cancer cell-targeted photoimmunotherapy using ML7710 laser system. Intratumoral injection of IL-15 was more effective than intraperitoneal in suppressing tumor growth and inducing intratumoral immune responses, Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2023

 Modulight Spotlights: LASER-SHARP RESEARCH – April 2023 Metastases remain the leading cause of cancer-related deaths worldwide. To combat this problem, Ruben V. Huis in ‘t Veld et al. combined immune checkpoint inhibitors with a light-activated virus-drug conjugate in their preclinical study. As published in Cancer Immunology, Immunotherapy journal, the combination was effective against metastatic tumors and in most cases even resulted in complete responses to therapy. ​​ Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our Continue reading →

Immune checkpoint inhibition combined with targeted therapy using a novel virus‑like drug conjugate induces complete responses in a murine model of local and distant tumors

Published in: Cancer Immunology, Immunotherapy Authors: Ruben V. Huis in ‘t Veld, Sen Ma, Rhonda C. Kines, Anneli Savinainen, Cadmus Rich, Ferry Ossendorp, Martine J. Jager    Published in: Cancer Immunology, Immunotherapy Authors: Ruben V. Huis in ‘t Veld, Sen Ma, Rhonda C. Kines, Anneli Savinainen, Cadmus Rich, Ferry Ossendorp, Martine J. Jager   AU-011 combination with immune checkpoint inhibitors (ICI) was studied in murine models. This has potential to improve treatment efficacy against metastatic tumors by abscopal immune effects. ICI was shown to increase AU-011 efficacy and also result in abscopal effect and induced complete responses in 75% of animals. ML6700 was used as illumination source for PDT. Metastases remain the Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023

 Modulight Spotlights: LASER-SHARP RESEARCH – February 2023 The nomination for Laser-Sharp Research goes to Mäki-Mikola et al. at University of Helsinki for their development of a dynamic cell culturing platform for light-activation studies. The developed platform has a flow chamber connected to a peristaltic pump, which creates a flow that resembles the natural fluid flow at the cell surfaces. ML6500 laser was used to release calcein from liposomes to validate the suitability of the platform for light-triggered drug release. Compared to traditional static cell culture Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022

   Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →

Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response

Published in: OncoImmunology Authors: Takuya Kato, Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi    Published in: OncoImmunology Authors: Takuya Kato, Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi   Myeloid-derived suppressor cells were selectively eliminated within tumors by Ly6G-targeted NIR-PIT, using ML7710 for in vitro and in vivo PIT. Significant tumor growth suppression and survival benefit, as well as abscopal effects, were observed in animal models, showing promise as a cancer immunotherapy.   Read the article here

A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada   The study investigated HSP90-targeted PDT for minimally invasive treatment of ductal carcinoma in situ (DCIS), benign breast cancer condition that has potential to progress into breast cancer. PDT with ML8500 combined to ML7710 resulted in effective in vitro cytotoxicity and with ML7710 in vivo, which was further potentiated with PD-L1 immune checkpoint inhibitors.   Read the article Continue reading →

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy

Published in: Cancer Immunology Research Authors: Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: Cancer Immunology Research Authors: Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   Cytotoxic T cells were partially depleted by NIR-PIT (using ML7710 for light activation) in mouse tumor models. PD-1 blockage led to rapid tumor progression compared with controls, indicating that rapid tumor progression, called hyperprogressive disease, after PD-1 blockage therapy can be attributed to imbalance between T cell populations.   Read the article here